DHR · Earnings call · 2026Q3T · Full report

Revenue Performance and Mix

DANAHER CORP /DE/ · 2026-10-21 · Importance 31 · Surprise 32

Life Sciences grew 4.5% in Q3 2026 and finished above management's expectations, marking its third consecutive quarter above internal expectations. Management attributed performance to improving end markets, commercial initiatives, and new product launches. Large pharma and biopharma remained robust; academic demand was still below historic levels but improved modestly sequentially. Clinical and applied markets, including microelectronics at Pall, continued to show strength.

Key facts

• Danaher’s third-quarter 2026 core revenue growth excluding respiratory revenue accelerated 100 basis points from the second quarter to 5.5%; including respiratory revenue, core revenue growth was 3%.
• Danaher’s Q3 2026 adjusted diluted net earnings per common share were $2.11, up approximately 11.5%.
• Danaher’s third-quarter 2026 core revenue growth excluding respiratory revenue was 5.5%, and adjusted operating profit margin was nearly 30%.